BRCA2 Polyclonal antibody

• 

  WB analysis using 29450-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 29450-1-AP (BRCA2 antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours.

BRCA2 Polyclonal Antibody for WB, ELISA

Cat No. 29450-1-AP

Publications(7)

Host / Isotype

Rabbit / IgG

Reactivity

Human and More (1)

Applications

WB, ELISA

Synonyms

BRCA2, BRCC2, breast cancer 2, early onset, BROVCA2, FACD, FAD, FAD1, FANCB, FANCD, FANCD1

Formulation:  PBS and Azide

PBS and Azide

Conjugate:  Unconjugated

Unconjugated

Size/Concentration: 

-/ -

Freight/Packing: -

Quantity

- +

Request bulk or custom quote

Add to Basket

Please visit your regions distributor:

---

Proteintech Guarantee

---

---

Tested Applications

• Positive WB detected in: HeLa cells, HepG2 cells, MCF-7 cells

Recommended dilution

• Western Blot (WB): WB : 1:1000-1:8000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Published Applications

• WB: See 7 publications below

Product Information

29450-1-AP targets BRCA2 in WB, ELISA applications and shows reactivity with Human samples.

• Tested Reactivity: Human
• Cited Reactivity: human
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: BRCA2 fusion protein Ag31064
• Full Name: breast cancer 2, early onset
• Calculated Molecular Weight: 384 kDa
• Observed Molecular Weight: 384 kDa
• GenBank Accession Number: NM_000059
• Gene Symbol: BRCA2
• Gene ID (NCBI): 675
• RRID: AB_2918309
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen affinity purification
• UNIPROT ID: P51587
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

BRCA2, also named as FACD and FANCD1, is involved in double-strand break repair and/or homologous recombination. BRCA2 may participate in S phase checkpoint activation. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer (BC) which also called susceptibility to familial breast-ovarian cancer type 2 (BROVCA2).

Publications

Species	Application	Title
human	WB	Int J Mol Sci; CSB Regulates Pathway Choice in Response to DNA Replication Stress Induced by Camptothecin; Authors - Nicole L Batenburg
human	WB	Aging (Albany NY); A prognostic risk model for programmed cell death and revealing TRIB3 as a promising apoptosis suppressor in renal cell carcinoma; Authors - Qingfeng Fu
human	WB	Nucleic Acids Res; CSB and SMARCAL1 compete for RPA32 at stalled forks and differentially control the fate of stalled forks in BRCA2-deficient cells; Authors - Nicole L Batenburg
human	WB	J Enzyme Inhib Med Chem; Design, synthesis, and evaluation of novel stilbene derivatives that degrade acidic nucleoplasmic DNA-binding protein 1 (And1) and synergize with PARP1 inhibitor in NSCLC cells; Authors - Leyuan Chen
human	WB	Oncol Lett; Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with a BRCA1 mutation; Authors - Wei Huang
human	WB	Prostate; Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH; Authors - Taihao Chang